Advanced search
Publication Cover
Cancer Biology & Therapy Volume 15, 2014 - Issue 1
Submit an article Journal homepage
872
Views
2
CrossRef citations to date
0
Altmetric
Journal Club

The androgen receptor transcriptional program in castration-resistant prostate cancer

Cell lines vs. tissue samples

Jeffrey E Roth Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA
,
Cody J Peer Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA
,
Douglas K Price Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USA
&
William D Figg Clinical Pharmacology Program; Office of the Clinical Director; National Cancer Institute; Bethesda, MD USACorrespondence[email protected]
Pages 16-18 | Received 17 Oct 2013, Accepted 10 Nov 2013, Published online: 19 Nov 2013

References

  • Lin D, Gout PW, Wang Y. Lessons from in-vivo models of castration-resistant prostate cancer. Curr Opin Urol 2013; 23:214 - 9; http://dx.doi.org/10.1097/MOU.0b013e32835e9f07; PMID: 23385975
  • Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011; 30:2719 - 33; http://dx.doi.org/10.1038/emboj.2011.158; PMID: 21602788
  • Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138:245 - 56; http://dx.doi.org/10.1016/j.cell.2009.04.056; PMID: 19632176
  • Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17:443 - 54; http://dx.doi.org/10.1016/j.ccr.2010.03.018; PMID: 20478527
  • Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. J Urol 2005; 173:342 - 59; http://dx.doi.org/10.1097/01.ju.0000141580.30910.57; PMID: 15643172
  • Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39:41 - 51; http://dx.doi.org/10.1038/ng1935; PMID: 17173048
  • Yu SQ, Lai KP, Xia SJ, Chang HC, Chang C, Yeh S. The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl 2009; 11:39 - 48; http://dx.doi.org/10.1038/aja.2008.44; PMID: 19098932
  • Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013; 23:35 - 47; http://dx.doi.org/10.1016/j.ccr.2012.11.010; PMID: 23260764
  • Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39:311 - 8; http://dx.doi.org/10.1038/ng1966; PMID: 17277777
  • Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67:5033 - 41; http://dx.doi.org/10.1158/0008-5472.CAN-06-3332; PMID: 17510436
  • McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010; 28:495 - 501; http://dx.doi.org/10.1038/nbt.1630; PMID: 20436461
  • Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27:2022 - 9; http://dx.doi.org/10.1200/JCO.2008.17.2882; PMID: 19289629
  • Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113:913 - 23; PMID: 15067324
  • Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11 - 22; http://dx.doi.org/10.1016/j.ccr.2010.05.026; PMID: 20579941

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.